Genomics

Sumitomo Pharma takes license to CRISPR/Cas9 patent portfolio

ERS

ERS Genomics Limited (“ERS”) is pleased to confirm finalization of a license agreement with Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”) granting Sumitomo Pharma non-exclusive access to the fundamental CRISPR/Cas9 intellectual property portfolio held by ERS.

ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Eighty-nine patents are held in over eighty countries, including 3 patents in Japan with broad coverage of the use of CRISPR/Cas9.

ERS CEO Eric Rhodes had the following statement: “We have been working with Sumitomo Pharma’s group for some time and are pleased to finally be able to announce this agreement. Sumitomo Pharma has a reputation worldwide for excellence and vision, and we look forward to seeing how CRISPR/Cas9 will enhance their internal research programs and lead to more effective drugs.”

Expanding on the regional aspect of the deal, Eric added: “Japan has one of the most developed biotechnology sectors in the world and we hope this partnership with Sumitomo Pharma is a signifier of a growing presence in this country. This represents ERS’s 16th license deal in Japan.”

Financial details of the agreement are not disclosed.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.

PR Newswire

PR Newswire empowers communicators to identify and engage with key influencers, craft and distribute meaningful stories, and measure the financial impact of their efforts. Cision is a leading global provider of earned media software and services to public relations and marketing communications professionals.

Related posts

S2 Genomics Announces Distribution Agreement with Techtum Lab AB

Business Wire

Healthtech Company Maze Therapeutics Welcomes Atul Dandekar

Business Wire

Nucleus Genomics raises $18 million in funding in one year

PR Newswire